ライフサイエンスコーパス: urine protein

1 is inadequate to abolish the serial 24-hour urine protein.

2 o-creatinine ratio (PCR) are used to measure urine protein.

3 on rates of 30 mL/min/1.73 m(2) and over and urine protein 0.75 g/24 hours and over on stable doses o

4 sed on the reduction in pretreatment 24-hour urine protein (24-hour UP) levels: complete response (ki

5 ian creatinine of 0.97 mg/dl, median 24-hour urine protein 3.1 g/day, and 32% had nephrotic syndrome.

6 Proteinuria was defined as urine protein 300 mg/24 h at 1 year after conversion to

7 d neutrophil gelatinase-associated lipocalin urine protein (55.6 +/- 21.3 mug/mL versus 2.7 +/- 0.53

8 nt interaction was detected between baseline urine protein and ACEI therapy (P = 0.003).

9 PE-evoked increments and decrements in urine protein and creatinine clearance, respectively, we

10 Urine protein and creatinine ratio (uPr/uCr) was used to

11 eak, which was assessed by measuring 24-hour urine protein and Evans blue dye, was used as a marker o

12 Clinical parameters including urine protein and glomerular filtration rate were measur

13 Urine protein and microalbumin did not change in either

14 centage agreement ranged from 80.5% for both urine protein and urine glucose testing to 91.4% for the

15 othalamate glomerular filtration rate [GFR], urine protein, and microalbumin) in 148 living kidney do

16 septal thickness, nerve involvement, 24-hour urine protein, and serum alkaline phosphatase.

17 The majority of urine proteins appear as cleavage products that are foun

18 IgE antibodies to alphaGal, swine urine proteins, beef and pork meat, serum albumin protei

19 Hence, our review attempts to identify urine protein biomarkers for LN that have been independe

20 In this paper, urine protein biomarkers were investigated because urine

21 The fingerprint of urine protein charge forms identifies the glomerular dis

22 inical rejection (n = 6), underwent in-depth urine protein compositional analysis with LC-MS/MS, and

23 Urine protein concentration appeared to be falsely incre

24 croalbumin varied from 3 to 34% of the total urine protein concentration.

25 reatment with the BDK inhibitor BT2 improved urine protein content, kidney hypertrophy, and kidney pa

26 Thirteen novel urine proteins contributed to the top 50% of ranked biom

27 tion rate (eGFR) <30 mL/min/1.73 m 2 or spot urine-protein creatine ratio >1 gm/gm and associated ris

28 iated lipocalin (NGAL), serum creatinine and urine protein creatinine ratio (uPCR), increase in the o

29 desonide, or placebo, stratified by baseline urine protein creatinine ratio (UPCR).

30 and key secondary endpoints were changes in urine protein creatinine ratio based on 24-hour urine co

31 sponse at 52 weeks defined as a composite of urine protein creatinine ratio of 0.5 mg/mg or less, sta

32 e key secondary endpoint was met as the mean urine protein creatinine ratio reduced from baseline by

33 mary endpoint was met at week 24 as the mean urine protein creatinine ratio was reduced from baseline

34 ients with thyroid dysfunction showed higher urine protein, creatinine and lipid levels and lower alb

35 n per 1.73 m(2), and persistent proteinuria (urine protein-creatinine ratio >=0.8 g/g or proteinuria

36 Urine protein-creatinine ratio (UPCR) and hematuria of s

37 tral laboratory normal range]) at screening, urine protein-creatinine ratio (UPCR) of 1.0 g/g or high

38 Baseline urine protein-creatinine ratio (UPCR), although high, wa

39 , percentage of participants with hematuria, urine protein-creatinine ratio (UPCR), and eGFR over 96

40 .1) mg/L, uric acid 7.2 (5.8-8.7) mg/dL, and urine protein-creatinine ratio 0.11 (0.08-0.20) mg/mg.

41 point was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sam

42 [IQR], 8-15), 371 (62%) were male, baseline urine protein-creatinine ratio was 0.33 (IQR, 0.12-0.95)

43 squares mean percent change from baseline in urine protein-creatinine ratio was statistically signifi

44 es in changes in hs-cTnI, CRP, uric acid, or urine protein-creatinine ratio were observed.

45 ics and risk factors, including the eGFR and urine protein-creatinine ratio.

46 (median age, 51 vs 53 years) and had higher urine protein-creatinine ratios (median, 98 vs 66 mg/g)

47 age and disease matched through analysis of urine (protein/creatinine) to generate 12 treatment pair

48 n before AMR, and many have proteinuria with urine protein/creatinine more than 0.5 in 41% and more t

49 (sC5b-9) and proteinuria measured by random urine protein/creatinine ratio (>=1mg/mg)) were required

50 ary end point was a prespecified decrease in urine protein/creatinine ratio and stabilization or impr

51 Urine protein/creatinine ratio at day 7 was elevated in

52 proliferative lupus nephritis and a baseline urine protein/creatinine ratio under 3 g/g.

53 lization characteristics, including eGFR and urine protein/creatinine ratio.

54 holesterol (209.1 vs. 204.3 mg/dL, P=0.973), urine protein/creatinine ratios (0.398 vs. 0.478 mg/dL,

55 Serum creatinine, urine protein/creatinine ratios, severity of histologic

56 At 52 weeks there was no difference in urine protein/creatinine, mean arterial pressure or scor

57 onsecutive visits, N = 739) and proteinuria (urine protein:creatinine ratio > 200, N = 573) by level

58 tes aged 18 years or older with proteinuria (urine protein:creatinine ratio [UPCR] 500-5000 mg/g) and

59 quantifying the spontaneous variation in the urine protein:creatinine ratio in SLE GN patients who ar

60 y Histological Index for disease chronicity, urine protein:creatinine ratio, and eGFR were not differ

61 32,110 person-years) from seven studies with urine protein dipstick measurements.

62 r kidney donors, and correlated results with urine protein dipstick readings and multiple other param

63 Twenty-four-hour urine protein electrophoresis (UPEP) was normal.

64 noclonal protein (>/=200 mg per 24 hours) in urine protein electrophoresis (UPEP).

65 Serum and urine protein electrophoresis and immunofixation, as wel

66 atio, urinary protein (g/24 hours), positive urine protein electrophoresis or immunofixation electrop

67 sed multiple myeloma (measurable by serum or urine protein electrophoresis or serum free light chains

68 easurements of monoclonal protein (serum and urine protein electrophoresis, serum free light chain, a

69 electrophoresis with immunofixation; 24-hour urine protein electrophoresis; and full-body skeletal im

70 tration up to 266 micromol/L (3.0 mg/dl) and urine protein excretion >900 mg/d.

71 Average baseline 24-h urine protein excretion (g/d) for treated and nontreated

72 measured protein-creatinine ratio and 24-hr urine protein excretion (n=192) and albumin-creatinine r

73 cial after adjustment for blood pressure and urine protein excretion (relative risk, 0.67 [95% CI, 0.

74 n-3 LCPUFA supplementation on the change in urine protein excretion (UPE) and on glomerular filtrati

75 e (ACE) inhibitors reduce blood pressure and urine protein excretion and slow the progression of chro

76 1.73 m(2) and >=60 mL/min per 1.73 m(2)) and urine protein excretion at screening (<=1.75 g/day and >

77 pressure levels was greater in patients with urine protein excretion greater than 1.0 g/d (P < 0.006)

78 129 mm Hg may be beneficial in patients with urine protein excretion greater than 1.0 g/d.

79 We quantitated preprocurement, timed urine protein excretion in 23 "normal" cadaver kidney do

80 tolic blood pressure of 110 to 129 mm Hg and urine protein excretion less than 2.0 g/d were associate

81 children (n = 103) had significantly greater urine protein excretion rates than the non-ADPKD childre

82 e levels increased to 4.3 +/- 0.8 mg/dl, and urine protein excretion rose to 0.64 +/- 0.28 mg/mg crea

83 creases in serum creatinine concentration or urine protein excretion were detected.

84 creatinine), but serum creatinine levels and urine protein excretion were not different from normal.

85 of systolic and diastolic blood pressure and urine protein excretion with kidney disease progression

86 r, income, education, previous CVD, baseline urine protein excretion, and baseline estimated GFR.

87 r increasing serum creatinine concentration, urine protein excretion, and diastolic blood pressure, a

88 n restriction on the rate of decline in GFR, urine protein excretion, and onset of end-stage renal di

89 Using quantitative proteomics, urine proteins from children with MCD and FSGS in the Cu

90 </=90 mL/min/1.73 m(2) (odds ratio, 2.0) and urine protein >200 mg/g (odds ratio, 2.3).

91 ange, up to 266 micromol/L (3.0 mg/dL), 24-h urine protein >900 mg/d, and at least 6 mo of follow-up.

92 Proteinuria was defined as Delta urine protein >=300 mg/24 h at 1 year after conversion t

93 At higher levels of urine protein, Hispanics had a significantly lower risk

94 ant into rats caused a threefold increase in urine protein in collections from 6 to 24 h after inject

95 teins) of 0.92 (reference range, 0.8-2.0), a urine protein level of 15 mg/dL (normal level, <20 mg/dL

96 with lupus nephritis, correlating well with urine protein levels and systemic lupus erythematosus di

97 n after kidney transplantation and typically urine protein levels are below 500 mg/d.

98 Using urine protein measurements from patients with Dent1 dise

99 improved understanding and interpretation of urine protein measurements in renal disease.

100 assessed by serial serum creatinine and 24-h urine protein measurements.

101 positive results; this can be corrected with urine protein normalization.

102 ndently in kidney (both RNA and protein) and urine (protein only), but not in plasma.

103 The patients with an initial urine protein/osmolality ratio >0.13 mg/L per mosmol per

104 .1232, P = 0.02) and partially correlated to urine protein (R(2) = 0.047, P = 0.12) and FBG (R(2) = 0

105 proteinuria, usCD163 normalization to total urine protein rather than creatinine provided the greate

106 er comparison cohort noninferiority study of urine protein screening for specific indications compare

107 We assessed FEPR (FEPR = [serum creatinine x urine protein] / [serum protein x urine creatinine], %)

108 ed frequency of hemoglobin A(1c), lipid, and urine protein testing; blood pressure measurement; and f

109 c analysis were used to identify patterns of urine proteins that are characteristic of the diseases.

110 Urine proteins that best distinguish active LN from inac

111 rate (<40 mL/min/1.73 m(2)) and proteinuria (urine protein to creatinine ratio >/=0.55 mg/mg) were si

112 interviewed and tested for proteinuria-spot urine protein to creatinine ratio (abnormal: >/=0.20 mg/

113 primary endpoint was change in proteinuria (urine protein to creatinine ratio [UPCR]) at nine months

114 There was a significant improvement of urine protein to creatinine ratio from a mean +/- SD of

115 ck positive level (approximately 300 mg/d or urine protein to creatinine ratio of 0.22), aggressive B

116 adequately anticoagulated thromboembolism; a urine protein to creatinine ratio of less than 1; and me

117 37) mL/min per 1.73 m2, and the median (IQR) urine protein to creatinine ratio was 1.54 (0.39-3.95).

118 Spot urine protein to creatinine ratio, spot urine albumin to

119 Proteinuria was measured by urine protein to creatinine ratio.

120 Early detection of urine protein to slow progression of chronic kidney dise

121 f 20-60 ml/min per 1.73 m(2)), and a 24-hour urine protein-to-creatinine ratio >/=800 mg/g to TGF-bet

122 e basis of urine dipstick and confirmed by a urine protein-to-creatinine ratio <200.

123 95% CI, 1.48 to 7.23; P<0.001); >/=0.30 g/g urine protein-to-creatinine ratio (HR, 2.44; 95% CI, 1.4

124 n urine albumin-to-creatinine ratio (ACR) or urine protein-to-creatinine ratio (PCR), during baseline

125 (FEPR) may better reflect kidney damage than urine protein-to-creatinine ratio (PCR).

126 Incident proteinuria was defined as a urine protein-to-creatinine ratio (UPCR) >200 mg/g, conf

127 tinued TDF, we estimated changes in eGFR and urine protein-to-creatinine ratio (UPCR) after 18 months

128 The primary endpoint for Part A was 24-hour urine protein-to-creatinine ratio (UPCR) after nine mont

129 nship of iptacopan versus placebo on 24-hour urine protein-to-creatinine ratio (UPCR) at three months

130 nsion (AASK; 38% female; mean GFR 46; median urine protein-to-creatinine ratio 81 mg/g; n =703) and r

131 an eGFR =38 ml/min per 1.73 m(2), and median urine protein-to-creatinine ratio [UPCR] =0.20 g/g).

132 ression to examine change in log-transformed urine protein-to-creatinine ratio after AKI, controlling

133 The mean urine protein-to-creatinine ratio decreased by 2% (95% C

134 or predictive of unsuccessful conversion was urine protein-to-creatinine ratio more than 1.

135 s 68.7 +/- 28.1 mL/min/1.73 m(2), and median urine protein-to-creatinine ratio was 0.1 (0.0-0.4) g/g,

136 among 2048 eligible participants, and median urine protein-to-creatinine ratio was 0.12 g/g (IQR, 0.0

137 The urine protein-to-creatinine ratio was measured at semian

138 rate, urine albumin-to-creatinine ratio and urine protein-to-creatinine ratio) did not (Rho = -0.222

139 cluded estimated glomerular filtration rate, urine protein-to-creatinine ratio, circulating antihuman

140 ort studies included annual ascertainment of urine protein-to-creatinine ratio, eGFR, BP, and medicat

141 luded sex, disease duration, APOL1 genotype, urine protein-to-creatinine ratio, estimated glomerular

142 as determined by the change from baseline in urine protein-to-creatinine ratio, was 40% lower in the

143 ndently associated with a 9% increase in the urine protein-to-creatinine ratio.

144 s per year; higher BP, serum phosphorus, and urine protein-to-creatinine ratio; lower serum albumin a

145 uria significantly decreased: mean change in urine protein-to-creatinine ratios was -2.53+/-3.76, P =

146 The mean urine protein (Up)-to-creatinine (c) ratio increased fro

147 r filtration rate was 38.7 mL/min, and 24-hr urine protein was 1.37 g.

148 Measurement of urine protein was the most common method of determining

149 ar filtration rate [eGFR], serum creatinine, urine protein) was measured annually.

150 blood urea nitrogen, urine specific gravity, urine protein, weight, age).

151 g hypertensive donors if kidney function and urine protein were normal.

152 Urine proteins were separated by two-dimensional electro

153 after conception and assessed the impact of urine protein where available.

154 +/-2,900 mg (mean+/-SD) of quantitated daily urine protein, which did not correlate with creatinine c

155 e interval [CI], -50.2% to -32.0%) change in urine protein with ravulizumab and -16.8% (95% CI, -31.8

156 I, -55.1% to -32.1%) change from baseline in urine protein with ravulizumab, and in patients who cros